Using CAR-based therapies to treat Alzheimer's disease
CAR-based approaches for the treatment of Alzheimer's Disease
This study is looking at new ways to use CAR therapies to help treat Alzheimer's disease by trying to remove harmful proteins from the brain, and it's aimed at people who want to be part of testing these promising treatments before serious damage happens.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10918121 on NIH RePORTER |
What this research studies
This research investigates innovative CAR-based approaches to target and treat Alzheimer's disease, a condition that affects millions of Americans. The study aims to explore how these therapies can potentially clear harmful beta-amyloid proteins from the brain, which are associated with the progression of Alzheimer's. By focusing on early intervention, the research seeks to address the disease before significant neurological damage occurs. Patients may be involved in trials that assess the safety and effectiveness of these new treatment methods.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals at risk for Alzheimer's disease, particularly those with early signs or genetic predispositions.
Not a fit: Patients with advanced Alzheimer's disease or those who do not exhibit early symptoms may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for Alzheimer's disease, potentially improving the quality of life for patients and slowing disease progression.
How similar studies have performed: While there have been numerous attempts to treat Alzheimer's with various therapies, this CAR-based approach is relatively novel and has not been extensively tested in this context.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Grajales-Reyes, Gary E. — Washington University
- Study coordinator: Grajales-Reyes, Gary E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.